Modified AAV Rep Gene With Artificial Intron for Cytotoxicity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of stable cell lines for high-titer production of Adeno-Associated Virus (AAV) is hindered by the cytotoxicity of Rep proteins, and existing production systems require additional viruses, posing safety risks and complexity.
Innovation Solution
A modified AAV rep gene with an artificial intron containing a stop cassette and specific attP and attB sites, recognized by a serine recombinase, is used to regulate Rep protein expression and facilitate AAV production, allowing for controlled induction of AAV replication and packaging without cytotoxic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If the AAV rep and cap genes are stably integrated or maintained in host cells to enable large-scale production, then productivity is improved, but the cytotoxicity of Rep proteins causes cell death or growth inhibition, worsening reliability
Solution Approach 1:
The patent integrates the rep and cap genes into the host cell genome in advance, but uses a conditional expression system where expression is blocked until induction. The tetracycline-responsive element (TRE) and tetracycline-controlled transactivator (tTA) system allow the genes to be present and ready for expression only when tetracycline or doxycycline is added, preventing cytotoxicity during cell line establishment while enabling high-level expression for production.
Solution Approach 2:
The patent implements dynamic control of Rep protein expression through the tetracycline-inducible system. Expression levels can be adjusted by varying the concentration of tetracycline or doxycycline in the culture medium, allowing optimization between cell health and AAV production. The system transitions from repression to activation based on the presence of the inducer molecule.
2Productivity
If traditional AAV production systems use additional helper viruses to enable replication and packaging, then productivity is improved, but device complexity and safety risks increase
Solution Approach 1:
The patent extracts the essential helper functions (replication and packaging) from separate virus particles and integrates them directly into the AAV genome itself. The rep gene provides replication functions and the cap gene provides packaging functions, both under the control of the P5 promoter. This eliminates the need for co-infection with adenovirus or other helper viruses, simplifying the system to a single viral component.
Solution Approach 2:
The patent combines the replication gene (rep), packaging gene (cap), and genome replication functions into a single integrated AAV construct. The P5 promoter drives expression of both rep and cap genes, and the ITRs facilitate genome replication, all within one viral genome, eliminating the need for separate helper virus systems.
3Productivity
If the P5 and P19 promoters are activated by adenovirus E1A gene to drive Rep protein expression, then productivity is improved, but object-generated harmful factors (cytotoxicity) worsen
Solution Approach 1:
The patent changes the regulatory parameter from adenovirus E1A-dependent promoter activation to tetracycline/doxycycline-inducible promoter activation. The TRE promoter and tTA system allow controlled expression based on the presence of the antibiotic inducer, enabling high-level expression only when needed for production while maintaining low expression during cell culture establishment, thereby reducing cytotoxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables efficient and safe production of AAV vectors by tightly controlling Rep gene expression, avoiding cytotoxicity and reducing the need for additional viruses, thereby improving yield and safety.
Implementation Method 1
an artificial intron containing a stop cassette and specific attP and attB sites, recognized by a serine recombinase
Data Source
AI summary
Recombinant constructs, cells and means for improved production of Adeno-Associated Viruses (AAVs) are described. Also described are methods of using the constructs and cells to produce recombinant AAVs.